cas 106635-86-3|| where to buy 2,6-Dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-amine

Nombre del producto:2,6-Dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-amine

IUPAC Name:2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-amine

Unidad de embalaje	Stock disponible	Precio($)
CM224514-100mg	in stock	ȀǯŔƻ
CM224514-500mg	in stock	ŔǕȀș
CM224514-1g	in stock	ŔŭŭƏ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 106635-86-3 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :106635-86-3; Fórmula molecular:C19H17F3N2O3; Punto de fusión:-; Código de sonrisas:NC1=C2N=C(OC)C=C(C)C2=C(OC3=CC=CC(C(F)(F)F)=C3)C(OC)=C1; Densidad:

: Número de catálogo:CM224514; Peso molecular:378.35; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Quinolines; Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.; Quinoline Price; if you have any question on quinoline price, we will give the professional answers to your short questions.

: Tafenoquine; 60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. The FDA has granted its investigational tafenoquine candidate orphan drug designation for the treatment of patients with acute babesiosis.
Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA and in Australia as KODATEF. It is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older.